Wednesday, November 13, 2013 7:08:09 PM
Thanks for reminding US why the CEO did the following!! FAST TRACK IS COMING AND WE ALL KNOW IT!!! $$$$$$$$$$$$
I would agree if that is all one had to go on was the CEO's words that would be far from helpful but we also have the actions of our CEO Nasrat Hakim. And as we know Actions speak louder than words.
1) Bought 11 Million shares and counting on the OPEN MARKET some while still working at Actavis!
2) Loaned the company $1 Million Dollars UNSECURED
*****So in our CEO's case he has backed up is words with irrefutable cash out of his own pocket! And I tend to pay attention to what CEO's say when they put up their own money.
Quote:
FDA has approved abuse deterrent technology and formulation in the past, one of the first was the company I was working for Alpharma Pharmaceutical which used a similar technique where they had the Naltrexone on the inside as a single bead and we covered the top of it with morphine sulfate. Company was sold to King Pharmaceutical and then it was sold to Pfizer mainly really because of this exceptional technology.
Our technology is better than that and that it is really difficult to distinguish the two beads from each other. And the beautiful thing about our technology and now that it is set where you have the Naltrexone all you have to do is the impregnate the opioid with any form you need whether it is morphine sulfate, oxycodone, hydromorphone or different strength.
I would agree if that is all one had to go on was the CEO's words that would be far from helpful but we also have the actions of our CEO Nasrat Hakim. And as we know Actions speak louder than words.
1) Bought 11 Million shares and counting on the OPEN MARKET some while still working at Actavis!
2) Loaned the company $1 Million Dollars UNSECURED
*****So in our CEO's case he has backed up is words with irrefutable cash out of his own pocket! And I tend to pay attention to what CEO's say when they put up their own money.
Quote:
FDA has approved abuse deterrent technology and formulation in the past, one of the first was the company I was working for Alpharma Pharmaceutical which used a similar technique where they had the Naltrexone on the inside as a single bead and we covered the top of it with morphine sulfate. Company was sold to King Pharmaceutical and then it was sold to Pfizer mainly really because of this exceptional technology.
Our technology is better than that and that it is really difficult to distinguish the two beads from each other. And the beautiful thing about our technology and now that it is set where you have the Naltrexone all you have to do is the impregnate the opioid with any form you need whether it is morphine sulfate, oxycodone, hydromorphone or different strength.
Recent ELTP News
- Form 8-K - Current report • Edgar (US Regulatory) • 04/02/2026 12:05:23 PM
- Elite Pharmaceuticals Announces Commercial Launch of Methadone Hydrochloride Tablets • Newsfile • 04/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 10:10:32 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Third Quarter of Fiscal Year 2026 (three months ended December 31, 2025) and Provides Conference Call Information • Newsfile • 02/17/2026 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/17/2026 09:06:15 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 09:35:26 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Third Quarter 2026 Financial Results on February 18, 2026 • Newsfile • 02/11/2026 09:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/13/2026 09:35:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/14/2025 10:10:23 PM
- Elite Pharmaceuticals, Inc. Reports Financial Results for the Second Quarter of Fiscal Year 2026 Ended September 30, 2025 and Provides Conference Call Information • Newsfile • 11/14/2025 09:19:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:11:38 PM
- Form 8-K/A - Current report: [Amend] • Edgar (US Regulatory) • 11/12/2025 10:19:32 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/12/2025 12:15:37 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/10/2025 12:15:46 PM
- Elite Pharmaceuticals, Inc. to Host Conference Call to Provide Corporate Update and Discuss Second Quarter 2026 Financial Results on November 17, 2025 • Newsfile • 11/10/2025 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 08/26/2025 09:17:39 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 08/22/2025 01:39:01 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/14/2025 08:37:09 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 08/08/2025 08:35:45 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/25/2025 10:05:07 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/10/2025 08:17:22 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 07/08/2025 08:15:11 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 07/08/2025 02:58:10 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 06/30/2025 08:27:51 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 06/30/2025 08:05:59 PM
